908 Devices, Inc. (MASS)

NASDAQ: MASS · IEX Real-Time Price · USD
19.74
+0.23 (1.18%)
Jun 29, 2022 11:47 AM EDT - Market open
1.18%
Market Cap 619.98M
Revenue (ttm) 44.97M
Net Income (ttm) -25.49M
Shares Out 31.41M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,273
Open 19.33
Previous Close 19.51
Day's Range 19.27 - 19.74
52-Week Range 12.60 - 39.82
Beta n/a
Analysts Buy
Price Target 27.03 (+36.9%)
Earnings Date Aug 3, 2022

About MASS

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extra... [Read more...]

Industry Medical Devices
IPO Date Dec 18, 2020
Employees 177
Stock Exchange NASDAQ
Ticker Symbol MASS
Full Company Profile

Financial Performance

In 2021, 908 Devices's revenue was $42.21 million, an increase of 56.93% compared to the previous year's $26.89 million. Losses were -$22.17 million, 72.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for MASS stock is "Buy." The 12-month stock price forecast is 27.03, which is an increase of 36.93% from the latest price.

Price Target
$27.03
(36.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

908 Devices Showcases Technology for Accelerating Mass Spec Workflows in Presentations at ASMS

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, is showcasing the use of its high-pressure ...

908 Devices to Participate in the William Blair 42nd Annual Growth Stock Conference

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will be participati...

908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates

908 Devices Inc. (MASS) delivered earnings and revenue surprises of 0% and 8.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

908 Devices Reports First Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for t...

908 Devices Advances MX908 Handheld Device Capabilities

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced updates to its MX908 h...

908 Devices Partners with Key Biomanufacturing Innovation Center

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, is partnering with the Advanced Mammalian Biomanufact...

908 Devices and CPI Team on Cell Culture Media Optimization for Improved Process Control in Bioprocessing Applications

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, is collaborating with UK-based, deep-tech innovation ...

908 Devices to Report First Quarter Financial Results on May 10, 2022

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financi...

Why 908 Devices Stock Rocketed 15% Higher Today

The niche healthcare company delivers a pair of convincing beats in its fourth quarter results.

908 Devices Reports Narrower Quarterly Loss As Handheld Devices Boost Q4 Sales

908 Devices Inc's (NASDAQ: MASS) Q4 FY21 revenue increased 177% Y/Y to $15.8 million, beating the consensus of $15.11 million. The increase was primarily driven by handheld revenue that increased 262%, ...

908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates

908 Devices Inc. (MASS) delivered earnings and revenue surprises of 33.33% and 4.91%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

908 Devices Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for t...

908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

BOSTON--(BUSINESS WIRE)--908 Devices has appointed Tony J. Hunt, President and CEO of Repligen Corporation to serve on its Board of Directors effective immediately.

Other symbols: RGEN

908 Devices to Report Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financia...

908 Devices to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will participate in...

908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced preliminary, unaudited...

908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSE: GSK) has ...

Other symbols: GSK

908 Devices and U.S. Forest Service Announce Development Collaboration

BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, and the United States Forest Service (USFS), an agenc...

908 Devices Teams With World-Renowned Guardian Centers of Georgia for First Responder Training

BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it is teaming with Guardian ...

908 Devices Announces Pricing of Public Offering

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of a publi...

908 Devices Announces Launch of Public Offering

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the launch of a public...

908 Devices Reports Third Quarter 2021 Financial Results

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for t...

908 Devices Launches Oligos Kit for its ZipChip CE-MS Device

PHILADELPHIA--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, announced at the American Societ...

908 Devices to Exhibit at ASMS and Present Key Developments in Accelerating Proteomics Workflows

BOSTON--(BUSINESS WIRE)--At the American Society of Mass Spectrometry (ASMS) conference October 31 to November 4 in Philadelphia, 908 Devices Inc. (Nasdaq: MASS) is presenting several talks and posters ...

908 Devices to Report Third Quarter Financial Results on November 4, 2021

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financi...